In vivo, chemerin-9 exerts an anti-inflammatory effect by targeting CMKLR1, thus restraining the development of several diseases, including atherosclerosis, Alzheimer's disease, and pancreatogenic diabetes [22–24]. Here, CMKLR1 is linked to early-onset autosomal dominant Alzheimer disease.